CEP or US DMF First? A Decision Guide for API Suppliers

The question arrives in almost every planning meeting: do we do the European certificate first or the American file? It sounds like a sequencing question with a technical answer. It is a commercial question, and the answer depends on which customers exist today rather than which markets look large on a slide.

Both instruments take real money and real months. Only one of them will be usable by the customers you already have.

What each instrument actually does

A certificate of suitability is an assessment outcome. A defined substance, made at a defined site, is found suitable for use against a pharmacopoeial monograph. Any marketing authorisation holder in the European Union can rely on it without re-documenting the substance.

A Type II drug master file is a repository. It holds the substance information confidentially and becomes reviewable only when a customer cites it in an application. Nothing is assessed until somebody references it.

The difference in commercial behaviour is the whole decision. A certificate can be used by customers you have never met. A drug master file can only be used by customers who are actively filing and who choose to name you.

The three variables that decide the order

Variable one: where your existing customers file

If your customers hold European generic dossiers, a certificate removes work from each of them. That is the argument you make in a quotation. If your pipeline is American, a certificate is a document they cannot use, and the file is the only thing that helps them.

The mistake is treating this as a market-size question. It is a customer-question. Two large markets and no customers in one of them produces a filing that ages on a shelf.

Variable two: whether a monograph exists

No monograph, no certificate. This single fact decides the order for any substance outside the pharmacopoeias, and it is often discovered late because teams assume the route is available for anything with a CAS number.

Where a monograph exists but is thin, the certificate is still available and the additional tests become the substance of the file. Where a monograph does not exist, the choice collapses to the file route plus, in Europe, the active substance master file used in its place.

Variable three: who maintains the document afterwards

Both instruments carry continuing obligations: change notification, periodic renewal or reporting, and consistency between what the document says and what the plant does. These obligations are usually estimated at filing and forgotten at renewal.

The relevant question is not which is cheaper to obtain. It is which one your organisation will keep current when nobody is asking about it. An out-of-date certificate is worse than no certificate, because it has already been quoted in a qualification file.

The comparison that matters

Dimension	CEP	Type II DMF
What it produces	An assessment outcome, usable by any EU authorisation holder	A confidential repository, usable only when cited
Customer action needed	None beyond referencing the certificate	Letter of authorisation plus a submission that cites the file
Visibility of assessment	Publicly listed status	Private; conclusions live in the customer's application
Commercial effect	Reduces work for prospects you have not met	Supports customers already filing
Availability	Requires a pharmacopoeial monograph	No monograph requirement
Maintenance	Change notification and periodic renewal	Amendments and annual reporting
Failure mode	Certificate lapses or scope drifts from the plant	Report not maintained; file goes stale while cited

The order most suppliers should choose

Where a monograph exists and European customers are real, the certificate first. It produces a document that works without a customer's cooperation, which makes it a sales instrument rather than a filing cost.

Where the customers are American or the substance has no monograph, the file first, because the certificate is either unusable or unavailable.

Where both pipelines are real, the sequence that wastes least is usually certificate first, then the file built from the same underlying data. The technical work overlaps heavily: characterisation, impurity origins, method validation, stability. Building the second document from the first is a project. Building them independently is two projects.

What the decision should not rest on

Three arguments that sound practical and are not.

"The certificate is faster." It may be, but a fast document nobody can use has no value. Speed matters after the route is chosen, not before.

"The file is cheaper." It is cheaper to prepare and more expensive to make useful, because its value depends on somebody else's submission timeline.

"We will do both eventually." Probably true. The question is which one you can sell against in the next twelve months, and that is decided by your existing pipeline, not by ambition.

A note on the third route

For suppliers without either instrument, the written confirmation route exists for material entering the European Union under specific conditions. It is narrower than a certificate, does not replace assessment of the substance, and is often mistaken for a licence. The three routes are compared in CEP, DMF or written confirmation.

Whichever is chosen, the buyer-side question stays the same: can this document be used without my supplier's further cooperation, and who keeps it current. See how a CEP or GMP certificate is actually verified and, for switching sources mid-registration, adding a second API source.

Primary sources: EDQM certification, the FDA Drug Master Files guidance, and ICH Q11 for the process and starting material expectations that both routes inherit.

Frequently asked questions

Can one set of data support both a CEP and a Type II DMF?

Largely yes. Characterisation, impurity origins, method validation and stability carry across. The differences are in format, in the starting material argument, and in how the monograph is addressed, which is specific to the certificate route.

Which filing do European customers prefer?

A certificate, because it removes substance documentation from their own dossier. A drug master file is usable in Europe in the form of an active substance master file, but it places work on the customer that a certificate does not.

Do I need a certificate to sell into the EU at all?

No. Material can enter under other arrangements, including documentation supplied by the customer's own filing. What changes is who carries the burden of demonstrating suitability, and that burden usually shows up in the price.

What if my substance has no pharmacopoeial monograph?

The certificate route is closed. The work moves to a master file in the relevant market, and the specification has to be justified from the process and from stability data rather than from a published text.

How long does each route take?

Both are measured in months and both are dominated by the applicant's own dossier quality and response speed rather than by the authority's queue. A file answered promptly at each round moves faster than a better file answered slowly.

Can I let one of the documents lapse if sales move elsewhere?

Only after customers stop citing it. Letting a document lapse while a customer's application or authorisation still references it creates a problem that belongs to them and will be traced back to you.